Article
Targeting regulatory T cells with Interleukin-2 treatment in type 1 diabetes: a…
medRxiv · 2017 · Eleonora Seelig
Key facts
| Title | Targeting regulatory T cells with Interleukin-2 treatment in type 1 diabetes: a response-adaptive, non-randomised, open-label trial of repeat doses of Aldesleukin (DILfrequency) |
|---|---|
| First author | Eleonora Seelig |
| Journal | medRxiv |
| Published | Nov 28, 2017 |
| DOI | 10.1101/223958 |
| Devices mentioned | K780428, K791373, K801244, K820613, K820614, K820942 |
| Product codes mentioned | CFE, JHI, JLW |
At a glance
- 1–9 FDA submissions mentioned
- 1–9 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1